Welcome to Novo Nordisk in the United States

Novo Nordisk Commitment to Transparency

As part of the Novo Nordisk Way – our global commitment to patients, our employees and our shareholders – transparency is part of the fabric of our organization.

Patient health and safety is our top priority. In order to advance the understanding of the needs of patients with diabetes and other chronic diseases, and the innovation of new therapies, we work directly with medical professionals in advisory and consulting relationships to help education healthcare providers on the appropriate use of our medicines.

Collaborations with physicians, research organizations, and healthcare institutions help us to drive innovation and develop new medicines, enhance quality of health education and identify patient needs.

We follow the highest ethical standards as well as all legal and regulatory requirements in our interactions with the medical community and our customers. We are completely transparent in our dealings with healthcare professionals and institutions related to our payments, prescription drug samples, clinical trial support, and grants and charitable contributions.

Novo Nordisk fully supports and adheres to all requirements of The Sunshine Act, commonly referred to as “Open Payments”. The Sunshine Act requires pharmaceutical, biologic and medical device manufacturers to annually report transfers of value to the U.S. government.

Open Payments promotes transparency by publishing the financial relationships between pharmaceutical manufacturers and healthcare providers (physicians and hospitals) on a publicly accessible website developed by the Centers for Medicare & Medicaid Services (CMS). Novo Nordisk submitted its second annual Sunshine transaction report to CMS on March 31, 2015 as required by law.

For more information on The Sunshine Act and Novo Nordisk’s engagement with healthcare providers, please contact the Compliance Department at NNISunshineCompliance@novonordisk.com.